Personalised medicine is pivotal in treating the most common cancer in women globally — breast cancer.
Cambridge University's Personalised Breast Cancer Programme has already identified multiple imperceptible mutations, changing patient treatment for the better. This programme has set a new standard: it was the first group — worldwide — to use Cambridge-developed Next Generation Sequencing as a routine, standard-of-care diagnostic and clinical tool.
These data-led approaches are the key to unlocking better treatments, and we will implement them widely across all cancer types.
Next steps
You can support the Breast Cancer Programme by giving a gift online now or to discuss your philanthropic objectives, please contact:
Make a gift now
Make a gift now to support by credit or debit card, or set up a direct debit:
Give nowOr, find out about other ways to give.
Director of Development, Cambridge University Health Partners
- Mary Jane Boland
- maryjane.boland@admin.cam.ac.uk
